Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Kalaris Therapeutics, Inc.

KLRS · Nasdaq · CIK 0001754068 · Healthcare · Biotechnology

INSIDER SIGNAL

56.2 / 100

1 buyers · 1 purchase transaction lines · $1.2M gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeModerate
RoleStrong
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+7.0 / 35
Purchase size+18.4 / 25
Role+20.0 / 20
Recency+0.8 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
  • ⚠ Purchase activity is becoming less recent
  • ✓ Role scores high · most senior buyer: Director,TenPercentOwner; TenPercentOwner

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
AKKARAJU SRINIVAS; Samsara BioCapital GP, LLC; Samsara BioCapital, L.P.; Samsara Opportunity Fund GP, LLC; Samsara Opportunity Fund, L.P.Director,TenPercentOwner; TenPercentOwner
○●
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS1
PURCHASE CONCENTRATION100%Largest buyer: AKKARAJU SRINIVAS; Samsara BioCapital GP, LLC; Samsara BioCapital, L.P.; Samsara Opportunity Fund GP, LLC; Samsara Opportunity Fund, L.P. · $1.2M
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-05-20–2026-05-20

Roles in the peak window: Director,TenPercentOwner; TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

56.2 / 100

Latest recorded score

→ +0.0 ptsversus the previous recorded snapshot
  1. 56.3
  2. 56.3
  3. 56.3
  4. 56.2
  5. 56.2

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

2Purchases
1Sales
4Other Form 4 lines
4SEC filings · 365 days
BUYING1 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER3 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-28.5%
3M
-46.6%
6M
-62.5%
12M
-64.2%

Volatility & liquidity

Volatility
99.7%
Beta
—
Avg daily value
USD 607,262

Valuation

Market cap
USD 56.2M
P/E
—

Fundamentals

Profit margin
—
ROE
-55.1%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-04 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
331,876
Previous report
318,361
Avg daily volume
72,771
Days to cover
4.6

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-05-20AKKARAJU SRINIVAS; Samsara BioCapital GP, LLC; Samsara BioCapital, L.P.; Samsara Opportunity Fund GP, LLC; Samsara Opportunity Fund, L.P.Purchase (P)Common Stock244,300USD 4.83USD 1,179,969SEC filing ↗
2025-12-18AKKARAJU SRINIVAS; Samsara BioCapital GP, LLC; Samsara BioCapital, L.P.; Samsara Opportunity Fund GP, LLC; Samsara Opportunity Fund, L.P.Purchase (P)Common Stock479,847USD 10.42USD 5,000,006SEC filing ↗
2023-06-27GILEAD SCIENCES, INC.Purchase (P)Common Stock2,930,870USD 3.75USD 10,990,762SEC filing ↗
2022-04-26Bornstein Jeffrey SPurchase (P)Common Stock5,000USD 4.64USD 23,200SEC filing ↗
2022-02-10Bornstein Jeffrey SPurchase (P)Common Stock5,000USD 8.87USD 44,350SEC filing ↗
2020-08-03Jovan-Embiricos MoranaPurchase (P)Common Stock2,900,000USD 17.00USD 49,300,000SEC filing ↗
2020-08-03VAN BEEK JEROEN BPurchase (P)Common Stock3,000USD 17.00USD 51,000SEC filing ↗
2020-08-03Brainard DianaPurchase (P)Common Stock6,300USD 17.00USD 107,100SEC filing ↗
2020-08-03Atillasoy ErcemPurchase (P)Common Stock3,500USD 17.00USD 59,500SEC filing ↗

Form 4 evidence

7 transaction lines in the latest 365-day window; 451 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-05-20AKKARAJU SRINIVAS; Samsara BioCapital GP, LLC; Samsara BioCapital, L.P.; Samsara Opportunity Fund GP, LLC; Samsara Opportunity Fund, L.P.Purchase (P)Common Stock244,300USD 4.83USD 1,179,969SEC filing ↗
2026-05-20AKKARAJU SRINIVAS; Samsara BioCapital GP, LLC; Samsara BioCapital, L.P.; Samsara Opportunity Fund GP, LLC; Samsara Opportunity Fund, L.P.J (J)Common Stock86,314USD 0.00USD 0SEC filing ↗
2026-03-20Hagen Brett RSale (S)Common Stock1,915USD 6.72USD 12,869SEC filing ↗
Show recent Form 4 evidence (5 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-05-20AKKARAJU SRINIVAS; Samsara BioCapital GP, LLC; Samsara BioCapital, L.P.; Samsara Opportunity Fund GP, LLC; Samsara Opportunity Fund, L.P.Purchase (P)Common Stock244,300USD 4.83USD 1,179,969SEC filing ↗
2026-05-20AKKARAJU SRINIVAS; Samsara BioCapital GP, LLC; Samsara BioCapital, L.P.; Samsara Opportunity Fund GP, LLC; Samsara Opportunity Fund, L.P.J (J)Common Stock86,314USD 0.00USD 0SEC filing ↗
2026-03-20Hagen Brett RSale (S)Common Stock1,915USD 6.72USD 12,869SEC filing ↗
2025-12-22AKKARAJU SRINIVAS; Samsara Opportunity Fund GP, LLC; Samsara Opportunity Fund, L.P.Award / grant (A)Common Stock1,500,000USD 10.00USD 15,000,000SEC filing ↗
2025-12-18AKKARAJU SRINIVAS; Samsara BioCapital GP, LLC; Samsara BioCapital, L.P.; Samsara Opportunity Fund GP, LLC; Samsara Opportunity Fund, L.P.Purchase (P)Common Stock479,847USD 10.42USD 5,000,006SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerKLRS
CIK0001754068
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
ExchangeNasdaq

Data coverage

Local Form 4 history451 transaction lines from 2020-07-29 to 2026-05-20
10 P purchase lines · 345 S sale lines · 96 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.